New score for brain inflammation didn't predict relapses

Credibility

Interest

Key Takeaway

A proposed score to predict relapses in MOG antibody disease did not work well, but starting immunosuppressive treatment after the first attack was linked to fewer relapses.

What They Found

Researchers tested a score (MOG-AR) that uses age, sex, type of first attack, and treatment to guess who will have more attacks later. They looked at 190 patients from many centers and followed them for about 3.5 years on average. The score did not reliably separate patients who would relapse from those who would not. Only one clear link was found: people who received immunosuppressive medicines after their first attack had fewer relapses. In short, the score was not very accurate, but early treatment seemed to help lower relapse risk.

Who Should Care and Why

People with MOG antibody disease and their caregivers should care because the study says this specific scoring tool may not help decide who needs extra monitoring or treatment. Think of the score like a weather app that sometimes gets the forecast wrong; you would not plan a big trip based only on it. Doctors and nurses may still use clinical judgment rather than relying on this score alone when planning care. Patients who had a first attack should discuss with their care team whether starting immunosuppressive medicine could lower their chance of another attack.

Important Considerations

This study looked back at patient records (retrospective), which can miss some details and causes uncertainty. The score was tested in many centers, but it still may not apply to every person with MOGAD because people and treatments differ. The finding that treatment helped does not prove cause and effect without more controlled studies, so talk to your doctor before making treatment choices.

AI-generated summary — for informational purposes only, not medical advice

Categories:

MS Diagnostics Clinical Trials Early Research

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Neurology(R) neuroimmunology & neuroinflammation often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News